Market Overview

3 Charts That Show Why There's Gilead Sciences...And Then There's Everybody Else

3 Charts That Show Why There's Gilead Sciences...And Then There's Everybody Else
Related GILD
Portfolio Manager Says Now Is A Great Time To Buy Biotech
As Gilead's Outlook Dims, Argus Downgrades
Here's How Walmsley Just Completed a Clean Sweep at GlaxoSmithKline (GuruFocus)

The graphs below were produced by Capital Market Labs.

Except for recent price action, biotechnology has been one of the best-performing sectors for a long time. Within that group there are a number of top performers, and among that group is a singular best performer.

Gilead Sciences, Inc. (NASDAQ: GILD) is up 145 percent over the last two years and 23 percent in the last eight months.

On a financial scale, it has outperformed every mega-cap in the United States and dominated its peers.

Let’s look at three visuals.

First is a chart of the US mega caps above $50 billion in market cap with one-year net income growth on the y-axis and one-year total revenue on the x-axis.


Put simply, there’s Gilead, and then there’s everybody else.

Now, let’s quickly turn to a couple of peers and chart the time series of net income for Gilead, Biogen, Amgen and Celgene.


Take a look at the enormous jump over the last year on the green line (Gilead).

Finally, let's look at the same peer group in a time series of cash from operations.


Again, note exponential growth in the last year for Gilead, which has grown from about $4 billion in cash from operations to now over $10 billion.

Ophir Gottlieb can be found on Twitter @ophirgottlieb.

Posted-In: Technicals Trading Ideas Best of Benzinga


Related Articles (GILD)

View Comments and Join the Discussion!

Partner Center